YOLFTbeta
30

S.Biomedics Co. Ltd.

304360 · KQ · Healthcare / Biotechnology

18,670.00KRW-180.00 (-0.95%)

Price History

Full chart

Market Stats

Previous Close18,850.00
Open18,810.00
Day Range18,520.00 – 19,300.00
52-Week Range13,910.00 – 42,600.00
Volume10.46K
Market Cap261.33B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.47
50-Day Avg19,454.00
200-Day Avg27,979.90

About

S.Biomedics CO., LTD., a biopharmaceutical company, engages in the research and development of stem cells therapy products. Its product pipeline comprises TED-N, which is in phase 1/2a clinical development for the treatment of subacute spinal cord injury; TED-A9, which is in phase 1/2a clinical development for the treatment of parkinson's disease; FECS-Ad, which is 1/2a for the treatment of critical limb ischemia; FECS-DF, which is in phase 1/2 clinical development for the treatment of crows feet; TED-R for the treatment of macular degeneration; CF-TED-N for the treatment of stroke; and CF-FECS-DF for the treatment of wound. The company provides testing services; and owns platform technologies for developing cell therapy products. The company has a strategic partnership with Catalent, Inc. for the development and manufacturing of TED-A9. S.Biomedics CO., LTD. was founded in 2005 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODong-Wook Kim
  • Employees54
  • HeadquartersWooil Venture Town Building, Seoul, South Korea, Korea
  • Websitehttps://www.sbiomedics.com

Leadership

  • Dong-Wook KimCo-Chief Executive Officer
  • SeIl KangCo- Chief Executive Officer

Financials

Income Statement

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.87B12.11B13.11B13.73B16.55B
Growth (%)-+36.58%+8.22%+4.77%+20.49%
Cost of Revenue4.55B6.00B6.55B7.03B9.00B
Gross Profit4.32B6.11B6.55B6.71B7.55B
Gross Margin48.70%50.45%50.00%48.84%45.61%
Operating Expense8.95B9.85B12.51B11.98B15.89B
Operating Income-4.63B-3.74B-5.95B-5.28B-8.34B
Operating Margin-52.16%-30.91%-45.42%-38.41%-50.42%
EBITDA--2.97B-6.70B-3.24B-3.32B
EBITDA Margin--24.48%-51.09%-23.57%-20.03%
Net Income-5.67B-6.33B-7.52B-5.82B-8.12B
Net Income Margin-63.90%-52.23%-57.39%-42.38%-49.08%
R&D5.52B5.49B6.51B5.85B9.18B
R&D as % of Total Revenue62.30%45.31%49.64%42.59%55.47%
Interest Expense674.93M25.92M103.69M123.61M1.45B
Interest Expense % of Total Revenue7.61%0.21%0.79%0.90%8.77%

Balance Sheet

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets17.80B24.36B31.95B44.60B41.22B
Total Liabilities13.96B28.14B25.02B32.74B24.49B
Total Equity2.51B-3.78B6.93B11.86B8.68B
Cash6.13B4.07B1.41B4.48B6.09B
Net Debt-9.08B8.96B13.20B4.59B

Cash Flow

Currency: KRW2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.29B-3.21B-6.15B-3.50B-3.98B
Investing Cash Flow--6.87B-8.82B-10.35B-
Financing Cash Flow-8.02B12.32B16.91B-
Capital Expenditure490.28M1.11B1.85B1.68B4.38B
Free Cash Flow-3.78B-4.31B-8.00B-5.18B-8.36B
FCF to OCF114.91%134.57%130.04%147.86%210.13%

Earnings

Report DateJun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------
EPS Actual-148.12-178.76-166.96-172.19-351.47-140.19-166.42-192.84-253.30-198.03-40.99-191.31-552.42
Surprise-------------
Timing-------------

Key Statistics & Ratios

Market Cap261.33B
Enterprise Value217.91B
Trailing P/E0.00
Forward P/E0.00
Price / Sales15.85
Price / Book8.31
Revenue (TTM)16.49B
Gross Profit (TTM)8.13B
EBITDA-8.87B
Profit Margin-73.11%
Operating Margin-76.54%
Return on Equity-39.31%
Return on Assets-11.94%
Shares Outstanding12.39M
Shares Float9.62M
Beta1.47
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%